Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism

Overview of attention for article published in JCI Insight, November 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 3 X users

Readers on

mendeley: 8 Mendeley

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 41,387 followers.

RT @JCI_insight: Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism: https://t.co/GY1gNy7d4u @IowaMe…

Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism: https://t.co/GY1gNy7d4u @IowaMed #Oncology

The DNA methyltransferase inhibitor decitabine has been used to reactivate silenced genes & as a pretreatment for anticancer therapies. A recent paper explores adding low-dose decitabine following administration of chemo to bolster therapeutic effic…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.